-
Sarepta’s Amondys 45 and Vyondys 53 confirmatory trial fails to achieve statistical significance on primary endpoint
Sarepta has completed the ESSENCE study, which is a confirmatory trial aimed at supporting full
-
Solid plans to seek FDA guidance in 2026 for Duchenne Gene Therapy Candidate SGT-003 S
Solid Biosciences today reported an update on the progress of the INSPIRE DUCHENNE open label,
-
Books to Add to Your Holiday Shopping List This Year: Spotlight on Community Authors
In August, Quest had the privilege of spotlighting published authors living with neuromuscular disease and
-
I’m learning to accept that grief is part of my DMD caregiver journey
Last weekend, my husband and I cleaned out our storage unit. My husband loves that
